论文部分内容阅读
目的:探讨多西他赛为主的DCF方案治疗进展期胃癌的疗效和毒副反应。方法:63例经病理确诊的进展期胃癌患者随机分为DCF组(治疗组)和FOLFOX4组(对照组)治疗,2周期后评价疗效。结果:治疗组(31例)有效率(RR)为51.6%,中位疾病进展时间(mTTP)为5.5个月,中位生存期(MST)为9.0个月,1年生存率为41.9%;对照组(32例)RR为46.9%,mTTP为5.3个月,MST为8.8个月,1年生存率为40.6%,两组比较无显著性差异(P>0.05)。毒副反应:治疗组中性粒细胞减少发生率为87.1%,没有Ⅳ度中性粒细胞减少和治疗相关性死亡。对照组中性粒细胞减少发生率为50.0%,没有Ⅲ/Ⅳ度中性粒细胞减少,差异有非常显著性意义(P<0.005),治疗组周围神经毒性发生率为3.2%,对照组为40.6%,差异有非常显著性意义(P<0.001)。结论:DCF方案治疗进展期胃癌疗效较好,毒副反应可耐受,值得临床上推广应用。
Objective: To investigate the efficacy and side effects of docetaxel-based DCF regimen in the treatment of advanced gastric cancer. Methods: Sixty-three patients with advanced gastric cancer diagnosed by pathology were randomly divided into DCF group (treatment group) and FOLFOX4 group (control group), and the therapeutic effect was evaluated after two cycles. Results: The response rate (RR) was 51.6% in the treatment group (n = 31), the median time to disease progression (mTTP) was 5.5 months, the median survival time (MST) was 9.0 months and the 1 year survival rate was 41.9%. The RR of the control group (32 cases) was 46.9%, the mTTP was 5.3 months, the MST was 8.8 months, and the 1-year survival rate was 40.6%. There was no significant difference between the two groups (P> 0.05). Toxicities: The incidence of neutropenia in the treatment group was 87.1% with no grade IV neutropenia and treatment-related death. The incidence of neutropenia in the control group was 50.0%, there was no grade Ⅲ / Ⅳ neutropenia, the difference was significant (P <0.005), the incidence of peripheral neurotoxicity in the treatment group was 3.2%, and the control group was 40.6%, the difference was very significant (P <0.001). Conclusion: DCF regimen is effective in treating advanced gastric cancer and its toxicity is tolerable. It is worth to be popularized in clinic.